Ardelyx Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
28,928.00
31,623.00
24,026.00
-
42,000.00
2,607
Cost of Goods Sold (COGS) incl. D&A
592.00
302.00
829.00
1,295.00
8,400.00
3,144
Gross Income
28,336.00
31,321.00
23,197.00
1,295.00
33,600.00
537
SG&A Expense
31,201.00
32,885.00
52,586.00
111,600.00
98,715.00
90,410
EBIT
2,865.00
1,564.00
29,389.00
112,895.00
65,115.00
90,947
Unusual Expense
3,506.00
1,593.00
-
-
-
-
Non Operating Income/Expense
52.00
10.00
261.00
508.00
1,955.00
3,187
Pretax Income
6,423.00
3,147.00
29,650.00
112,387.00
63,160.00
91,294
Income Tax
141.00
67.00
29.00
-
1,179.00
4
Consolidated Net Income
6,564.00
3,214.00
29,621.00
112,387.00
64,339.00
91,298
Net Income
6,564.00
3,214.00
29,621.00
112,387.00
64,339.00
91,298
Net Income After Extraordinaries
6,564.00
3,214.00
29,621.00
112,387.00
64,339.00
91,298
Net Income Available to Common
6,564.00
3,214.00
29,621.00
112,387.00
64,339.00
91,298
EPS (Basic)
0.35
0.31
1.29
2.80
1.36
1.62
Basic Shares Outstanding
18,529.10
10,248.30
22,892.60
40,118.50
47,435.30
56,219.90
EPS (Diluted)
0.35
0.31
1.29
2.80
1.36
1.62
Diluted Shares Outstanding
18,529.10
10,248.30
22,892.60
40,118.50
47,435.30
56,219.90
EBITDA
2,273.00
1,262.00
28,560.00
111,600.00
62,476.00
88,269

About Ardelyx

View Profile
Address
34175 Ardenwood Boulevard
Fremont California 94555
United States
Employees -
Website http://www.ardelyx.com
Updated 07/08/2019
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicine for the treatment of renal diseases. It also focuses on the development of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development.